Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05212402 · ClinicalTrials.gov registry record · NA

Assessing the Effects of a Cannabidiol Derived From Hemp Supplement in Healthy Adults

A NA study of Healthy and Safety Issues, sponsored by University of South Carolina.

Completed
Registry status
NA
Development phase
56
Enrollment target
1
Study location

NCT05212402 is a NA study of Healthy and Safety Issues that has completed, run by University of South Carolina. The registered enrollment target is 56 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05212402, a NA study of Healthy and Safety Issues, has completed, sponsored by University of South Carolina.

COMPLETED
Registry status
NA
Development phase
56 participants
Enrollment target
1
Study location

Study Summary

The purpose of this prospective, randomized, double-blind, placebo-controlled trial is to assess the physiological, biochemical, and psychometric impacts of a brand-specific hemp-derived cannabidiol product in a sample of healthy adults.

Conditions Studied

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT Cannabinol

Study Locations (1)

South Carolina

  • University of South Carolina Sport Science Lab - Columbia

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2022-01-18
Est. Completion 2022-10-30
Phase NA

Sponsor

University of South Carolina

157 total trials

What the Registry Record Tells You About NCT05212402

The ClinicalTrials.gov registry entry for NCT05212402 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The listed sponsor is University of South Carolina, which has 157 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05212402 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT05212402 about?

NCT05212402 is a clinical study titled "Assessing the Effects of a Cannabidiol Derived From Hemp Supplement in Healthy Adults". The purpose of this prospective, randomized, double-blind, placebo-controlled trial is to assess the physiological, biochemical, and psychometric impacts of a brand-specific hemp-derived cannabidiol product in a sample of healthy adults.

What is the current status of trial NCT05212402?

This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2022-01-18. Estimated completion is 2022-10-30.

What conditions does trial NCT05212402 study?

This clinical trial studies the following conditions: Healthy, Safety Issues.

What interventions are being tested in trial NCT05212402?

The interventions under investigation include: Placebo (OTHER), Cannabinol (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05212402?

This trial is sponsored by University of South Carolina, which has 157 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05212402 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.